Trials / Completed
CompletedNCT04208399
A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379
A Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of JNJ-56136379
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Janssen Sciences Ireland UC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the pharmacokinetics (PK) of a single oral dose of JNJ-56136379 in participants with liver cirrhosis and impaired hepatic function when compared with healthy participants with normal hepatic function and no liver cirrhosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-56136379 | JNJ-56136379 will be administered orally in fed condition. |
Timeline
- Start date
- 2020-01-09
- Primary completion
- 2021-03-26
- Completion
- 2021-03-26
- First posted
- 2019-12-23
- Last updated
- 2021-04-20
Locations
1 site across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04208399. Inclusion in this directory is not an endorsement.